The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors

Cytokine and Growth Factor Reviews

Volumn 7, Issue 2, 1996, Pages 133-141

  Rusch, Valerie ^a   Mendelsohn, John ^a   Dmitrovsky, Ethan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

EGFR; Human tumors; Ligands; Therapeutic targets

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL; AUTOPHOSPHORYLATION; CANCER THERAPY; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMISTRY; CONFORMATIONAL TRANSITION; DRUG EFFECT; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GENE TARGETING; HEMATOPOIETIC CELL; HUMAN; HUMAN TISSUE; LIGAND BINDING; METABOLISM; NEOPLASM; SHORT SURVEY; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ANIMALIA;

EID: 0030206987     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00016-0     Document Type: Short Survey

References (64)

1. 1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61, 203-212.
2. 2. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992, 9, 383-391.
3. 3. Lax I. Mitra AK, Ravera C et al. Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. J Biol Chem 1991, 266, 13828-13833.
4. 4. Hurwitz DR, Emanuel SL, Nathan MH et al. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem 1991, 266, 22035-22043.
5. 5. Greenfield C, Hiles I, Waterfield MD et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J 1989, 8, 4115-4123.
6. 6. Schlessinger J. Signal transduction by allosteric receptor oligomerization. Trends Biochem Sci 1988, 13, 443-447.
7. 7. Honnegger AM, Kris RM, Ullrich A, Schlessinger J. Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc Natl Acad Sci USA 1989, 86, 925-929.
8. 8. Honegger AM, Schmidt A, Ullrich A, Schlessiger J. Evidence for epidermal growth factor (RGF)-induced inter-molecular autophosphorylation of the EGF receptors in living cells. Molec Cell Biol 1990, 10, 4035-4044.
9. 9. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415-1421.
10. 10. Zhong Z, Wen Z, Darnell JE Jr. Stat3 and Stat4: Members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 1994, 91, 4806-4810.
11. 11. Heim MH, Kerr IM, Stark GR, Darnell Jr JE. Contribution of STAT SH2 groups to specific Interferon signaling by the Jak-STAT pathway. Science 1995, 267, 1347-1349.
12. 12. Shuai K, Ziemiecki A, Wilks AF et al. Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jaka and Stat proteins. Nature 1993, 366, 580-582.
13. 13. Qureshi SA, Salditt-Georgieff M, Darnell Jr JE. Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc Natl Acad Sci USA 1995, 92, 3829-3833.
14. 14. Zhong Z, Wen Z, Darnell JE Jr. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264, 95-98.
15. 15. Markowitz SD, Molkentin K, Gerbic C, Jackson J, Stellato T, Willson JKV. Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor-receptor in normal adenomatous human colon epithelium. J Clin Invest 1990, 86, 356-362.
16. 16. Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R. Expression in rat fibroblasts of a human transforming growth factor-α cDNA results in transformation. Cell 1986, 46, 301-309.
17. 17. Riedel H, Massoglia S, Schlessinger J, Ullrich A. Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts. Proc Natl Acad Sci USA 1986, 85, 1477-1481.
18. 18. Valverius EM, Bates SE, Stampfer MR et al. Transforming growth factor α production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Molec Endocr. 1989, 3, 203-214.
19. 19. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC. Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 1990, 61, 1121-1135.
20. 20. Di Marco E, Pierce JH, Fleming TP et al. Autocrine interaction between TGF-α and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1989, 4, 831-838.
21. 21. Stampfer MR, Pan CG, Hosoda J, Bartholemew J, Mendelsohn J, Yaswen P. Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. Exp Cell Res 1993, 208, 175-188.
22. 22. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin invest 1995, 95, 1897-1905.
23. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996, 12, 1397-1403.
24. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J. Cell Biol 1995, 131, 235-242.
25. 25. Fontanini G, Vignati S, Bigini D et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 1995, 31A, 178-183.
26. 26. Neal DE, Bennett MK, Hall RR et al. Epidermal growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1998, i, 366-368.
27. 27. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T. Clinical significance of the expression of epidermal growth factor and its receptor in oesophageal cancer. Cancer 1991, 68, 142-148.
28. 28. Nichólson S, Richard J, Sainsbury C et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991, 63, 146-150.
29. 29. Haeder M, Rotsch M, Bepler G et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988, 48, 1132-1136.
30. 30. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 1992, 52, 3089-3094.
31. 31. Derynck R, Goeddel DV, Ullruch A et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor by human tumors. Cancer Res 1987, 47, 707-712.
32. 32. Kaseda S, Ueda M, Ozawa S, Ishihara T, Abe O, Shimizu N. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 1989, 42, 16-20.
33. 33. Gorgoulis V, Giatromanolaki A, Karameris A et al. Epidermal growth factor receptor expression in squamous cell lung carcinomas: An immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material. Virchows Arch A Path Anat Histol 1993, 423, 295-302.
34. 34. Berger MS, Gullick WJ, Greenfield C, Evans S, Addis BJ, Waterfield MD. Epidermal growth factor receptors in lung tumours. J. Pathol 1987, 152, 297-307.
35. 35. Gorgoulis V, Aninos D, Mikou P et al. Expression of EFG, TGF-α and EGFR in squamous cell lung carcinomas. Anticancer Res 1992, 12, 1183-1188.
36. 36. Dazzi H, Hasleton PS, Thatcher N et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 1989, 59, 746-749.
37. 37. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990, 50, 7077-7080.
38. 38. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 1987, 55, 513-516.
39. 39. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68, 162-165.
40. 40. Sobol RD, Astarita RW, Hofeditz C et al. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Nat Cancer Inst 1987, 79, 403-407.
41. 41. Hwang DL, Tay Y-C, Lin SS, Lev-Ran A. Expression of epidermal growth factor receptors in human lung tumors. Cancer 1986, 58, 2260-2263.
42. 42. Lee JS, Ro JS, Eisbruch A et al. Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor gene. Cancer Res 1988, 48, 4045-4048.
43. 43. Lee JS, Ro JY, Sahin A, Hittelman W. Expression of epidermal growth factor receptor (EGFR): A favorable prognostic factor for surgically resected non-small cell lung cancer. Proc ASCO 1989, 8, A878 (Abstract).
44. 44. Rusch V, Vaselga J, Cordon-Cardo C et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53, 2379-2385.
45. 45. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 1995, 55, 1365-1372.
46. 46. Modjtahedi H, Eccles SA, Box G, Styles J, Dean CJ. Anti-tumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 1993, 22, 129-146.
47. 47. Dean C, Modjtahedi H, Eccles S, Box G, Styles J. Immunotherapy with antibodies to the EGF receptor. Int J Cancer 1994, 8, 103-107.
48. 48. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma In vitro and in nude mice. J Nat Cancer Inst 1988, 82, 1605-1611.
49. 49. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in thymic mice and anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984, 44, 1002-1007.
50. 50. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994, 269, 27595-27602.
51. 51. Masui H, Moroyama T, Mendelsohn J. Mechanism of anti-tumour activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 1986, 46, 5592-5598.
52. 52. Perez-Soler R, Donato NJ, Shin DM et al. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J Clin Oncol 1994, 12, 730-739.
53. 53. Divgi CR, Welt S, Kris M et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Nat Cancer Inst 1991, 83, 97-104.
54. 54. Vollmar AM, Banker DE, Mendelsohn J, Herschman HR. Toxicity of ligand and antibody-directed ricin a-chain conjugates recognizing the epidermal growth factor receptor. J Cell Physiol 1987, 131, 418-425.
55. 55. Ozawa S, Ueda M, Ando N, Abe O, Minoshima S, Shimizu N. Selective killings of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 1989, 43, 152-157.
56. 56. Kirk J, Carmichael J, Stratford IJ, Harris AL. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF. Br J Cancer 1994, 69, 988-994.
57. 57. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Nat Cancer Inst 1993, 85, 1327-1333.
58. 58. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-EGF receptor monoclonal antibodies plus cis-Diamminedichloroplatinum (cis-DDP) on well established A431 cell xenografts. Cancer Res 1993, 53, 4637-4642.
59. 59. Buchdunger E, Trinks U, Mett H et al. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc Natl Acad Sci USA 1994, 91, 2334-2338.
60. 60. Thompson AM, Bridges AJ, Fry DW, Kraker AJ, Denny WA. Tyrosine kinase inhibitors. 7, 7-amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido [4,3-d]pyrimidmes: A new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem 1995, 38, 3780-3788.
61. 61. Fry DW, McMichael A, Singh J, Dobrusin EM, McNamara DJ. Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ 1. Peptides 1994, 15, 951-957.
62. 62. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin, Carcinogenesis 1995, 16, 1741-1745.
63. 63. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/Neu receptors by tyrphostins. J Biol Chem 1993, 268, 11134-11142.
64. 64. Fry DW, Kraker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor kinase. Science 1994, 265, 1093-1095.